10-K: Profound Medical Reports 51% Revenue Growth, Widens Net Loss

Profound Medical Corp. reported a 51% increase in revenue for the year ended December 31, 2025, driven by strong TULSA-PRO sales, but also saw its net loss widen to $42.57 million.

Summary

• Revenue for the year ended December 31, 2025, increased by 51% to $16.098 million, up from $10.680 million in 2024.
• Gross profit rose by 62% to $11.393 million in 2025, compared to $7.037 million in 2024, with gross margin improving from 66% to 71%.
• Net loss for 2025 widened to $42.570 million, a 53% increase from the $27.816 million net loss in 2024.
• Operating expenses increased by 31% to $52.647 million in 2025, primarily due to higher R&D and SG&A expenses.
• Research and development (R&D) expenses increased by 21% to $20.596 million, driven by increased headcount, CAPTAIN trial enrollment, and material/travel costs.
• Selling, general and administrative (SG&A) expenses increased by 39% to $32.051 million, due to increased sales force, commission payments, and conference travel.
• Cash and cash equivalents stood at $59.723 million as of December 31, 2025, up from $54.912 million in 2024.
• The company completed a public offering and private placement in December 2025, raising gross proceeds of $36.000 million and $6.450 million, respectively, for a total of $42.450 million.
• Profound Medical Corp. expects existing cash and sales to fund operations for at least the next 12 months from the filing date.
• The TULSA-PRO system received Category 1 CPT codes effective January 1, 2025, with Medicare National Average payments of $13,479 for Hospital Outpatient (HOPD) and $10,874 for Ambulatory Surgical Centers (ASCs).
• The CAPTAIN trial, comparing TULSA-PRO to robotic radical prostatectomy for intermediate-risk prostate cancer, completed enrollment of 211 subjects in 2025, with perioperative outcomes showing TULSA's superiority in blood loss, length of stay, pain, and recovery.
• The company remediated a material weakness in internal control over financial reporting related to revenue recognition under ASC 606 during 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive. While the significant revenue growth and positive clinical trial outcomes for TULSA-PRO are strong indicators of commercial progress and market potential, the widening net loss and substantial increase in operating expenses highlight the ongoing capital intensity and execution risks inherent in scaling a medical device company.

Positives

• Total revenue increased by a significant 51% to $16.098 million in 2025, indicating strong commercial traction.
• Gross profit improved by 62% to $11.393 million, and gross margin increased from 66% to 71%, reflecting better pricing and sales growth.
• The TULSA-PRO system received favorable Category 1 CPT codes effective January 1, 2025, with higher Medicare National Average payments for HOPD ($13,479) and ASCs ($10,874) compared to traditional prostate cancer treatments.
• The CAPTAIN trial completed enrollment of 211 subjects in 2025, a significant milestone for comparing TULSA-PRO to robotic radical prostatectomy.
• Perioperative outcomes from the CAPTAIN trial demonstrated TULSA-PRO's statistical and clinical superiority over robotic prostatectomy in key areas like blood loss, length of stay, post-procedure pain, and recovery to baseline activities.
• The company successfully remediated a previously identified material weakness in internal control over financial reporting related to revenue recognition.
• Cash and cash equivalents increased to $59.723 million by year-end 2025, supported by recent financing activities.
• The company expects to have sufficient cash to fund operations for at least the next 12 months.

Negatives

• Net loss for the year ended December 31, 2025, widened by 53% to $42.570 million, indicating increased operational costs outstripping revenue growth.
• Operating expenses increased substantially by 31% to $52.647 million, driven by higher R&D and SG&A costs.
• R&D expenses increased by 21% to $20.596 million, reflecting ongoing investment but contributing to the net loss.
• SG&A expenses increased by 39% to $32.051 million, indicating significant spending on sales and marketing efforts.
• The company has a limited operating history and a history of operating losses, with an accumulated deficit of $287.740 million as of December 31, 2025.
• The company's cash runway is based on assumptions that may prove inaccurate, potentially requiring additional financing sooner than anticipated.
• The company was in breach of a CIBC Credit Agreement covenant on August 1, 2025, related to unrestricted cash, though a waiver was obtained and the covenant was amended.

Risks

• Limited operating history and history of operating losses, with no assurance of future profitability.
• Business is capital intensive, requiring significant investment for commercialization and product development, with no guarantee of available financing on acceptable terms.
• Exposure to foreign currency risk, which will increase with U.S. commercialization, and no hedging strategy in place.
• Reliance on collaborative partners (Philips, Siemens, GE Healthcare) for sales, marketing, and distribution, with risks if these partnerships are unsuccessful or terminated.
• Potential failure to achieve commercialization and future product development goals within expected timeframes or at all.
• Products, including TULSA-PRO, may not achieve or maintain expected levels of market acceptance due to various factors like safety, efficacy, cost-effectiveness, and competition.
• Successful commercialization depends on maintaining strong working relationships with physicians/clinicians, and their misuse of products could lead to negative outcomes.
• Reliance on compatibility of products with specific MRI scanners, and challenges in expanding compatibility or maintaining existing relationships.
• Availability of coverage and adequate reimbursement from third-party payers is crucial for commercial success and is not guaranteed.
• Reliance on in-house sales and marketing capabilities requires substantial build-up and commitment of resources, which may be unsuccessful.
• Potential manufacturing scaling issues due to limited experience in assembling and testing products at significant scale, leading to supply shortages or quality control problems.
• Dependence on third parties for manufacturing and supply of components, including single-source suppliers, posing risks of delays, increased costs, and supply interruptions.
• Significant competition from existing and future medical devices or surgical methodologies for prostate and other diseases.
• Clinical trial data may not support regulatory approvals/clearances or reimbursement coverage, or may be inconsistent with prior results.
• Reliance on third parties for clinical trial planning, conduct, and regulatory advice, with risks of unsatisfactory performance or missed deadlines.
• Dependence on key managerial personnel, particularly the CEO, and intense competition for qualified personnel in the medical device field.
• Research and development carries substantial risk, and the company may not be able to expand its product portfolio successfully.
• Potential for product liability claims, which can be expensive and may exceed insurance coverage, and warranty claims on products.
• Rising insurance costs could negatively impact profitability.
• Increasing dependence on sophisticated information technology systems, with risks of cyber-attacks, data breaches, and other security incidents.
• Risks and challenges associated with the development and use of AI, including security risks, legal/regulatory actions, and reputational harm.
• A portion of employees are unionized, and potential labor disruptions could adversely affect the business.
• Damage or destruction of facilities could lead to delays and negative impact on revenues.
• Risks associated with the acquisition of businesses and technologies, including integration difficulties and failure to realize anticipated benefits.
• Extensive government regulation and oversight in the U.S. and abroad, with failure to comply leading to enforcement actions.
• Inability to obtain, or significant delays in obtaining, FDA clearances or other regulatory authorizations for product candidates or enhancements.
• Difficulties in attracting and enrolling patients for clinical trials, leading to increased costs and delays.
• Subject to fines, penalties, or injunctions for promoting unapproved or off-label uses or engaging in false/misleading promotion.
• Compliance with quality systems regulations for medical device companies is difficult, time-consuming, and costly, with potential for non-compliance.
• Modifications to cleared/approved products may require new regulatory clearances/approvals, or lead to recalls/cessation of marketing.
• Products causing or contributing to death/serious injury or malfunctioning could trigger medical device reporting regulations and enforcement actions.
• Legislative or regulatory reform of healthcare systems could affect profitability and business.
• Subject to fraud and abuse laws, anti-bribery laws, environmental laws, and privacy/security regulations, with violations leading to severe penalties.
• Inadequate funding for government agencies (FDA, SEC) could hinder their ability to perform functions critical to the business.
• Breach of license agreements with third parties could lead to loss of important intellectual property rights.
• Proprietary rights may not adequately protect technologies, and patents may be challenged, invalidated, or circumvented.
• Patent protection may expire before commercial value is maximized, leading to increased competition.
• Substantial costs from litigation or other proceedings related to intellectual property rights enforcement.
• Risks from international operations, including difficulties in management, price/currency controls, political instability, and trade measures.
• Future sales or issuances of securities may cause the market price of Common Shares to decline.
• Market price of Common Shares may fluctuate significantly due to various factors beyond control.
• Rights of shareholders may differ from those in a U.S. corporation due to Ontario, Canada incorporation.
• As a smaller reporting company, reduced reporting requirements may make Common Shares less attractive to investors.
• Unfavorable commentary or downgrades by equity research analysts could cause stock price decline.
• Potential for securities litigation, which is expensive and diverts management attention.
• Never paid dividends and do not anticipate paying any in the foreseeable future, making capital appreciation the sole source of gain.
• Inability to satisfy Sarbanes-Oxley requirements or ineffective internal controls over financial reporting could question financial statement reliability.
• Default under existing debt (CIBC Credit Agreement) not waived could materially adversely impact financial results and stock price.
• As a foreign private issuer, following home country corporate governance practices instead of certain Nasdaq requirements may afford less protection to shareholders.
• Operating as a U.S. public company incurs significantly increased costs and management time.
• Loss of foreign private issuer status in the future could result in significant additional costs and expenses.
• Difficulty for U.S. investors to effect service of process or enforcement of actions against the company or its directors/officers under U.S. federal securities laws.
• Potential classification as a passive foreign investment company (PFIC) for U.S. federal income tax purposes, resulting in adverse tax consequences for U.S. shareholders.
• Requirement to register as an investment company under the Investment Company Act could lead to significant compliance costs and restrictions.

Future Outlook

Profound Medical Corp. expects its expenses to increase due to continued commercialization of TULSA-PRO and Sonalleve. The company anticipates its existing cash and product sales will fund operating expenses and capital expenditures for at least the next 12 months. Future growth depends on successfully developing new product candidates and improvements, which may require additional capital through equity/debt financings or strategic partnerships. The company is also evaluating regulatory strategies for additional potential indications for Sonalleve.

Management Comments

• "We are a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue utilizing our platform technologies."
• "The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum."
• "TULSA employs real-time MR guidance for pixel-by-pixel precision to preserve prostate disease patients urinary continence and sexual function, while killing the targeted prostate tissue via a precise sound absorption technology that gently heats it to kill temperature (55-57C)."
• "We believe that TULSA-PROs controlled and relatively gentle heating process may result in lower post procedural pain and complications, reduced potential of life affecting side effects, and in significantly desirable shrinkage of the prostate via resorption of the dead tissue over time, which may provide a longer-term durable benefit."
• "We believe that in the hands of trained physicians, our systems have the ability to provide customizable, incision-free ablative therapies with the precision of real-time MRI visualization and thermometry, focused ultrasound and closed-loop temperature feedback control."
• "We believe that our technology offers clinicians and appropriate patients a better alternative to traditional surgical or radiation therapies, with respect to clinical outcomes, side effects and recovery time."
• "The increase in R&D expenses was largely due to increased headcount, increased enrolment for the CAPTAIN trial and higher material expenditures and travel associated with the trial, and increased testing and design modification. These expenses promote the ongoing development and improvement of the products while further strengthening the commitment to a reliable and customizable product."
• "The increase in SG&A was due to increased sales force and commission payments, increased travel for conferences, customer visits and educational events throughout the year."
• "Based on our current operating plans, we expect that our existing cash and sales of our products and services will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the filing date of this Annual Report."

Industry Context

StockSavvy.ai notes that Profound Medical Corp. operates in the highly competitive and innovative medical device sector, specifically targeting MRI-guided ablation therapies. The company's focus on incision-free and radiation-free procedures aligns with a broader industry trend towards minimally invasive treatments that offer improved patient outcomes, faster recovery times, and reduced side effects. The successful completion of the CAPTAIN trial and the favorable CPT code assignment for TULSA-PRO position the company to potentially disrupt traditional prostate cancer and BPH treatment markets, which are dominated by more invasive surgical (e.g., robotic radical prostatectomy) and radiation therapies. The partnerships with major MRI manufacturers like Philips, Siemens, and GE Healthcare are critical for integration into existing healthcare infrastructure, a common strategy for medical device companies to accelerate adoption. The widening net loss, despite revenue growth, is typical for commercial-stage medical device companies investing heavily in market penetration, R&D, and clinical evidence generation.

Comparison to Industry Standards

• TULSA-PRO's perioperative outcomes in the CAPTAIN trial demonstrated statistical and clinical superiority over robotic radical prostatectomy (RP) in blood loss, length of stay, post-procedure pain, and recovery to baseline activities. RP is currently considered the gold-standard surgical treatment for intermediate-risk prostate cancer, but carries risks of significant side effects like long-term erectile dysfunction and urinary incontinence.
• The TULSA-PRO system's ability to ablate even large prostates (120 cubic centimeters or larger) with a transurethral approach offers an advantage over some competing focal ablation techniques like trans-rectal HIFU, which is limited to prostate volumes smaller than 40 cubic centimeters and may require adjunct procedures like TURP.
• TULSA-PRO's incision-free, controlled heating process, with real-time MRI thermometry, is positioned as a better alternative to traditional surgical or radiation therapies, aiming for lower post-procedural pain, faster recovery, and reduced potential for side effects that diminish quality of life, as supported by a March 2021 Journal of Urology study.
• The Sonalleve system's non-invasive treatment for uterine fibroids and osteoid osteoma compares favorably to surgical options (hysterectomy, myomectomy) and radiofrequency ablation (RFA) for osteoid osteoma, which are more invasive and carry risks of complications and radiation exposure.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to or aware of any proceedings that are believed to have a material adverse effect on the business, financial condition, or results of operations. Litigation, regardless of outcome, can have an adverse impact due to costs and diversion of management resources.

Related Party Transactions

• No related party transactions or series of similar transactions to which the company has been or will be a party since January 1, 2024, other than compensation arrangements, where the amount involved exceeds the lesser of $120,000 or 1% of the average of total assets.

Stakeholder Impact

• **Shareholders:** Potential for increased value from commercialization success and positive clinical trial results (CAPTAIN trial), but diluted by recent equity offerings and ongoing net losses. Governance changes aim to align management interests with shareholders.
• **Patients:** Improved treatment options for prostate cancer, BPH, uterine fibroids, and osteoid osteoma through less invasive, incision-free, and radiation-free therapies (TULSA-PRO, Sonalleve) with potentially better quality of life outcomes.
• **Physicians/Clinicians:** Access to advanced MRI-guided ablation systems (TULSA-PRO, Sonalleve) with new CPT codes for TULSA procedures, potentially increasing adoption and reimbursement. Requires training and adherence to protocols to avoid misuse.
• **Employees:** Increased headcount in R&D and sales, indicating growth opportunities. Unionized employees in Finland have good labor relations. Share-based compensation plans aim to attract and retain talent.
• **Creditors (CIBC):** Company has a revolving line of credit with CIBC, with financial covenants that have been breached and waived, indicating some financial risk, but current compliance is maintained.

Next Steps

• Continue commercialization of the TULSA-PRO system in the United States.
• Continue development and commercialization of the TULSA-PRO system and the Sonalleve system globally.
• Pursue additional regulatory approvals in international jurisdictions.
• Invest in research and development and clinical studies to increase evidence for customer coverage and reimbursement.
• Consider synergistic strategic acquisitions to expand platform technology applications and commercial footprint.
• Expand compatibility of systems with other MRI scanners, requiring design changes and potentially additional regulatory approvals.
• Conduct additional research and clinical trials to obtain reimbursement coverage for TULSA-PRO and other authorized products.
• Monitor and comply with evolving regulatory requirements, including the New EU MDR and U.S. cybersecurity regulations for cyber devices.
• Finalize reauthorization of the medical device user fee program by Congress by end of September 2027 to avoid disruption in FDA performance goals.

Key Dates

Recommendation

Profound Medical Corp. demonstrates strong revenue growth and promising clinical data for its TULSA-PRO system, particularly with the favorable CPT code assignment and positive perioperative results from the CAPTAIN trial. These factors suggest significant market potential and a competitive edge in the minimally invasive treatment space. However, the company continues to incur substantial net losses and increased operating expenses as it scales commercialization and R&D. While the recent capital raise provides liquidity for the next 12 months, the business remains capital intensive with inherent risks in market acceptance, regulatory compliance, and manufacturing scale-up. Given the strong product potential balanced against ongoing profitability challenges and the need for future financing, a 'hold' recommendation is appropriate for investors to monitor execution and progress towards sustainable profitability.

Keywords

Profound Medical, TULSA-PRO, Sonalleve, MRI-guided therapy, Prostate cancer, BPH, Uterine fibroids, Medical device, Thermal ablation, Focused ultrasound, FDA clearance, CE Mark, Health Canada approval, CAPTAIN trial, Financial results, Revenue growth, Net loss, Operating expenses, Capital raise, SEC filing, 10-K, Healthcare technology, AI-powered medical devices, Corporate governance, Risk factors